kniearthrose knee osteoarthritis
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients included in the CL3-12911-018 study and having received the CL3-12911-018 study treatment (strontium ranelate 1g/2g or placebo) for at least one year (at least 365 days of treatment during the CL3-12911-018 study) having signed the informed consent form for this new study
Exclusion criteria
Exclusion criteria: -unlikely to cooperate in the study (such as patients suffering from dementia) -patients unable to provide the information requested by the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Knee joint replacement in the target knee (knee followed in the CL3- 12911-018 study). - Knee surgery or other procedure (arthroscopy, osteotomy or other). | — |
Countries
Netherlands